Trials / Unknown
UnknownNCT02038738
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- Sponsor
- Ochsner Health System · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.
Conditions
- Neuroendocrine
- Neuroendocrine Tumor
- Neuroendocrine Cancer
- Neuroendocrine Carcinoma
- Carcinoid
- Carcinoid Tumor
- Islet Cell Tumor
- Apudoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography. |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2019-03-01
- First posted
- 2014-01-17
- Last updated
- 2014-01-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02038738. Inclusion in this directory is not an endorsement.